anticanc
agent
long
histori
particular
herb
use
cancer
patient
found
old
literatur
cancer
chemotherapi
scienc
began
nitrogen
mustard
discov
period
time
treat
lymphoma
effect
attract
much
attent
medic
circl
promot
develop
mani
anticanc
drug
includ
synthet
compound
medicin
plant
antibiot
present
cancer
chemotherapi
form
one
import
disciplin
cancer
treatment
china
cancer
chemotherapi
establish
foundat
peopl
republ
china
govern
paid
attent
cancer
control
problem
end
auspic
chines
academi
scienc
intern
confer
antibiot
held
beij
task
investig
new
anticanc
antibiot
propos
scientist
plan
advanc
scienc
technolog
china
initi
anticanc
drug
research
also
includ
mani
unit
affili
research
institut
medic
school
pharmaceut
compani
well
hospit
began
join
research
program
end
movement
great
leap
forward
encourag
peopl
search
method
drug
combat
cancer
consid
danger
diseas
difficult
research
problem
sinc
massiv
screen
chines
medicin
herb
folk
remedi
cancer
treatment
spread
cooper
work
effect
agent
certain
kind
cancer
patient
prove
meanwhil
beij
nation
bureau
cancer
prevent
treatment
affili
ministri
health
peopl
republ
china
organ
consist
branch
organ
one
cooper
group
anticanc
drug
research
dr
b
xu
appoint
head
group
order
organ
collabor
task
exchang
inform
vari
antitumor
agent
period
meet
confer
held
differ
citi
china
instanc
nation
confer
tumor
pharmacolog
chemotherapi
begun
time
continu
recent
year
record
confer
may
seen
tabl
sever
promis
antineoplast
agent
found
effect
six
cooper
research
program
organ
includ
camptotheca
acuminata
cephalotaxu
fortunei
cantharidin
colchicum
autumnal
crotalaria
sessiliflora
l
curcuma
zedoaria
berg
rose
joint
effort
differ
unit
number
therapeut
drug
studi
detail
experiment
clinic
recommend
clinic
use
product
new
anticanc
drug
commonli
use
countri
also
investig
china
use
nativ
materi
method
alkaloid
vinca
rosea
nitrogen
mustard
deriv
antimetabolit
other
time
china
isol
abroad
period
thought
earli
stage
anticanc
drug
research
china
mani
specialist
area
gain
much
knowledg
experi
also
learn
great
deal
foreign
literatur
meanwhil
fundament
basi
research
educ
product
anticanc
drug
establish
later
influenc
nation
polici
reform
open
china
door
open
specialist
scientist
opportun
go
abroad
learn
new
achiev
world
enrich
knowledg
cancer
chemotherapi
new
disciplin
cell
kinet
molecular
tumor
pharmacolog
standard
evalu
procedur
new
anticanc
agent
laboratori
clinic
effici
screen
method
qualifi
clinic
trial
combin
chemotherapi
differ
cancer
forth
introduc
china
lead
institut
field
shanghai
institut
materia
medica
simm
chines
academi
scienc
ca
institut
materia
medica
beij
imm
chines
hangzhou
nan
zhengzhou
tianjin
taian
fuzhou
academi
medic
scienc
cam
institut
pharmacolog
toxicolog
chines
academi
militari
medic
scienc
shanghai
institut
pharmaceut
industri
institut
antibiot
beij
tumor
hospit
locat
beij
shanghai
guangzhou
play
import
role
rais
level
cancer
chemotherapi
chines
practic
activ
make
exchang
knowledg
search
produc
new
antitumor
drug
within
short
period
time
major
wellknown
anticanc
prepar
world
could
alreadi
produc
china
satisfi
clinic
need
drug
includ
number
china
develop
agent
export
countri
vinca
alkaloid
camptothecin
tabl
show
basic
antitumor
drug
use
clinic
time
also
meant
popular
antitumor
agent
could
manufactur
suppli
chines
pharmaceut
compani
afterward
basic
antitumor
drug
chang
period
old
drug
replac
new
agent
effect
compound
recent
number
target
drug
biotherapeut
agent
also
includ
recent
year
knowledg
concern
natur
cancer
increas
greatli
molecular
oncolog
molecular
pharmacolog
genet
engin
disciplin
make
scope
anticanc
drug
research
much
broader
particular
mani
new
target
interf
tumor
growth
metastasi
disclos
base
new
find
mean
new
method
techniqu
mani
new
drug
includ
cytostat
agent
tyrosinekinas
inhibitor
angiogenesi
inhibitor
antisign
transduct
drug
antineoplast
antibodi
differentiationinduc
agent
new
gener
antimetabolit
cytotox
agent
develop
chines
research
laboratori
pharmaceut
plant
activ
take
part
collabor
work
foreign
pharmaceut
compani
organ
mani
new
find
drug
prepar
alreadi
discov
present
nearli
new
anticanc
drug
found
chines
pharmaceut
market
clinic
hospit
thousand
scientif
paper
relat
investig
product
differ
antitumor
agent
publish
journal
book
onlin
network
annual
chines
specialist
mani
import
contribut
field
found
differ
channel
review
achiev
obtain
china
close
relat
work
tabl
actinomycin
actinomycin
c
j
report
antineoplast
action
simm
activ
substanc
isol
cultur
inhibit
percentag
kinas
activ
gener
measur
inhibit
phosphoryl
peptid
substrat
ad
enzym
reaction
presenc
inhibitor
b
human
lung
adenocarcinoma
cell
line
overexpress
egfr
curv
determin
five
concentr
ic
valu
concentr
need
inhibit
cell
growth
determin
curv
media
streptomyc
melanochromogen
includ
obtain
soil
sampl
collect
dalian
region
investig
detail
systemat
studi
one
substanc
call
antibiot
actinomycin
k
prove
anticanc
properti
pharmacolog
experi
show
could
inhibit
sarcoma
ehrlich
ascit
carcinoma
spindl
cell
sarcoma
sarcoma
ak
mice
antitumor
effect
stronger
actinomycin
c
toxicolog
mechanist
studi
actinomycin
k
recommend
clinic
trial
clinic
data
show
antibiot
exert
remark
therapeut
effect
choriocarcinoma
malign
lymphoma
afterward
actinomycin
k
approv
manufactur
name
gengshengmeisu
later
work
show
actinomycin
k
consist
two
compon
new
substanc
littl
amount
identifi
actinomycin
confirm
antitumor
agent
us
time
sever
year
purifi
actinomycin
k
produc
chines
pharmaceut
factori
equal
actimomycin
provid
clinic
use
found
laboratori
actinomycin
k
could
inhibit
rna
synthesi
induc
nucleolu
segreg
mean
quantit
electron
microscop
method
prove
actinomycin
k
inhibit
transcript
process
rdna
rrna
tumor
cell
provid
new
data
elucid
mechan
action
simm
chemist
synthes
dozen
new
deriv
actinomycin
k
test
antitumor
activ
none
found
better
actinomycin
k
data
relationship
chemic
structur
activ
compound
meaning
studi
plant
alkaloid
camptothecin
isol
famou
chines
tree
c
acuminata
report
strong
antitumor
activ
murin
leukemia
cell
time
research
simm
paid
much
attent
tree
isol
differ
activ
principl
bark
trunk
leav
fruit
test
antitumor
activ
vitro
vivo
sever
investig
us
report
camptothecin
could
caus
sever
bladder
toxic
weak
therapeut
effect
thu
drug
drop
clinic
trial
laboratori
persist
studi
find
antidot
toxic
meanwhil
found
hcpt
isol
fruit
tree
possess
higher
antitumor
activ
lower
toxic
camptothecin
seri
studi
hcpt
put
product
clinic
use
report
result
intern
confer
publish
seri
paper
relat
hydroxycamptothecin
new
attent
paid
analog
camptothecin
promot
novel
investig
deriv
last
year
irinotecan
topotecan
analog
hydroxycamptothecin
becom
popular
anticanc
drug
wide
use
tumor
hospit
differ
countri
alreadi
known
activ
metabolit
possess
much
higher
potenc
time
suggest
great
potenti
explor
better
drug
hcpt
exist
work
pursu
china
hcpt
basic
common
anticanc
drug
produc
sever
pharmaceut
compani
use
clinic
differ
cancer
patient
mainli
gastrointestin
carcinoma
tumor
head
neck
mark
therapeut
effect
investig
point
lacton
open
form
hcpt
ie
sodium
prepar
inact
accord
experiment
data
lacton
close
open
form
hcpt
effect
tumor
growth
latter
less
potent
could
convert
close
form
certain
condit
present
new
find
concern
deriv
camptothecin
achiev
institut
describ
later
cephalotaxu
famou
tree
speci
asia
distribut
china
principl
isol
tree
includ
harringtonin
analog
report
antitumor
action
murin
leukemia
model
afterward
clinic
result
cancer
treatment
report
china
time
sever
research
group
differ
institut
systemat
investig
cephalotaxusderiv
alkaloid
harringtonin
hrt
homoharringtonin
hhrt
independ
isol
simm
imm
beij
subject
preclin
clinic
studi
result
collabor
work
hospit
pharmaceut
plant
hrt
hhrt
got
approv
clinic
use
product
although
hhrt
includ
list
basic
cancer
therapeut
drug
china
mani
year
clinic
trial
us
confirm
definit
therapeut
action
drug
leukemia
patient
yet
recommend
product
countri
seen
tabl
lentinan
popular
anticanc
adjuv
agent
frequent
use
cancer
chemotherapi
drug
prepar
lentinu
edod
berg
sing
contain
polysaccharid
number
chines
tradit
medicin
polyporu
versicolor
grifolia
umbellata
pachyman
ginseng
ganoderma
lucidum
consist
differ
kind
polysaccharid
enhanc
bodi
immun
act
like
biologicalrespons
modifi
polysaccharidepeptid
psp
isol
coriolu
versicolor
show
certain
antitumor
activ
similar
psk
without
notic
side
effect
experiment
studi
mixtur
lucid
ganoderma
lucid
ganoderma
spore
mlglg
show
high
dosag
could
produc
inhibitori
action
growth
human
lung
tumor
xenograft
nude
mice
lin
cowork
report
mechan
antitumor
action
g
lucidum
mainli
relat
inmunoenhanc
activ
modul
mani
compon
immun
system
antigenpres
cell
nk
cell
b
lymphocyt
clinic
prepar
g
lucidum
alway
use
combin
therapi
play
support
role
bodi
function
decreas
toxic
caus
cytotox
drug
chines
medicin
tcm
mention
section
massiv
anticanc
screen
work
complet
certain
effect
agent
found
literatur
accord
six
therapeut
principl
tcm
treatment
cancer
patient
remedi
medicin
herb
found
possess
antitumor
activ
laboratori
screen
find
activ
substanc
unit
use
agent
also
obtain
activ
substanc
briefli
describ
lycobetain
ungeremin
semisynthet
deriv
lycorin
isol
lycori
radiata
began
studi
famili
amarylidacea
plant
sever
alkaloid
prove
antineoplast
activ
hemanthamin
pretazettin
narciclasin
forth
lycobetain
lbt
found
strongest
antitumor
substanc
clinic
trial
also
indic
lbt
could
exert
therapeut
effect
ovarian
carcinoma
gastric
carcinoma
without
mark
toxic
preferenti
inhibit
chromatin
activ
induc
singleor
doublestrand
breakag
crosslink
lbt
could
intercal
dna
dnabind
properti
might
classifi
new
group
dna
intercal
plant
origin
unfortun
inject
cancer
patient
intraperiton
intraven
side
effect
local
irrit
occur
frequent
thu
drug
ceas
manufactur
studi
improv
prepar
take
lead
compound
still
consid
tcm
cantharidin
prepar
kind
beetl
mylabri
phalerata
pall
employ
treatment
neoplast
diseas
pharmacolog
studi
show
definit
anticanc
action
anim
tumor
liver
carcinoma
patient
exhibit
certain
benefici
effect
present
deriv
disodium
cantharid
norcantharidin
hydroxycantharidimid
methylcantharidimid
compound
prepar
use
clinic
sever
activ
principl
isol
tradit
chines
herbal
medicin
oridonin
rabodosia
rubesen
esophag
carcinoma
henan
provinc
indirubin
indigo
naturali
chronic
myelocyt
leukemia
beij
curcuma
aromatica
cervic
carcinoma
irisquinon
seed
iri
palasii
radiosensit
effect
tianjin
citi
also
use
treatment
differ
kind
cancer
patient
detail
investig
still
warrant
tcm
miner
arsen
compound
also
employ
cancer
treatment
intraven
inject
arsen
trioxid
could
exert
therapeut
effect
acut
promyelocyt
leukemia
remiss
rate
use
combin
alltran
retino
acid
atra
efficaci
increas
markedli
complet
remiss
rate
remark
effect
confirm
countri
gain
intern
recognit
recent
year
oral
administr
arsen
sulfid
prepar
deriv
old
chines
remedi
also
demonstr
antileukemia
effect
treatment
differ
kind
cancer
patient
medicin
formula
compound
prescript
frequent
use
tradit
chines
medic
practic
rather
difficult
determin
import
element
efficaci
andor
mode
action
recent
realgarindigo
naturali
formula
rif
employ
treat
promyelocyt
leukemia
investig
detail
indic
tetraarsen
tetrasulfid
princip
compon
indirubin
tanshinon
iia
includ
formula
adjuv
ingredi
abovement
element
mix
one
formula
could
produc
synergist
effect
better
singl
agent
separ
work
model
analyz
mechan
tcm
formula
compound
recip
help
encourag
conduct
detail
studi
relat
tradit
chines
formula
recip
well
known
nitrogen
mustard
mechlorethamin
first
synthet
anticanc
drug
possess
definit
antineoplast
action
narrow
antitumor
spectrum
high
toxic
hundr
thousand
deriv
synthes
test
antitumor
activ
small
number
effect
compound
prove
safe
use
treatment
cancer
patient
cyclophosphamid
melphalan
lomustin
thiotepa
chlorambucil
lomustin
busulfan
drug
mainli
act
dna
protein
cancer
cell
caus
crosslink
dna
strand
interf
replic
dna
transcript
rna
classifi
alkyl
agent
period
time
synthet
chemist
pharmacologist
simm
activ
join
search
better
synthet
anticanc
drug
test
synthet
compound
agent
differ
chemic
structur
vari
mechan
action
discov
effect
agent
systemat
preclin
work
compound
recommend
clinic
trial
forth
chines
institut
number
effect
compound
anticanc
activ
also
success
develop
section
effect
drug
present
briefli
mecaphan
methoxysarcolysin
methoxysarcolysin
design
synthes
institut
pan
other
deriv
sarcolysin
chemic
structur
pbi
chloroethyl
aminoomethoxyphenylalanin
pharmacolog
studi
show
exhibit
mark
inhibit
sarcoma
ehrlich
ascit
carcinoma
spindl
cell
sarcoma
mice
yashida
ascit
carcinoma
guerin
carcinoma
walker
carcinosarcoma
rat
use
oral
intraperiton
easili
absorb
highest
blood
concentr
attain
min
oral
administr
concentr
drop
steadili
higher
concentr
found
bone
marrow
kidney
liver
drug
distribut
throughout
mani
intern
organ
excret
urin
h
smaller
amount
detect
fece
inhibit
mitosi
nucleic
acid
metabol
cancer
cell
mechan
action
similar
alkyl
agent
clinic
data
show
effect
chronic
myelocyt
leukemia
hodgkin
diseas
seminoma
tumor
case
chronic
myelocyt
leukemia
evalu
effect
treat
among
case
achiev
complet
remiss
case
recurr
found
followup
period
drug
includ
edit
chines
pharmacopeia
nformyl
sarcolysin
nf
dlpbi
aminonformylphenylalanin
synthes
han
cowork
report
nf
possess
strong
antitumor
action
yashida
sarcoma
walker
tumor
reticulumcel
sarcoma
ascit
carcinoma
other
nf
inhibit
protein
synthesi
incorpor
nucleic
acid
caus
abnorm
chromosom
tumor
cell
mean
electron
microscopi
progress
degener
mitochondria
increas
number
lysosom
notic
nf
administ
oral
absorpt
gastrointestin
tract
incomplet
clinic
studi
demonstr
drug
could
exert
mark
therapeut
effect
seminoma
patient
surviv
rate
reach
nf
administ
alon
also
employ
combin
therapi
radiat
surgeri
simm
systemat
studi
antitumor
activ
para
ortho
metaisom
phenylalanin
deriv
substitut
one
hydrogen
atom
methyl
group
phenylalanin
experiment
result
show
orthoisom
ocaphan
possess
strong
antitumor
effect
number
anim
tumor
includ
rabbit
tumor
model
carcinoma
clinic
found
effect
treatment
patient
malign
pleural
effus
cancer
head
neck
fairli
toxic
hemopoiet
organ
alreadi
known
cytotox
action
bear
relat
chemic
reactiv
chlorin
atom
mustard
group
postul
high
chemic
reactiv
ocaphan
might
relat
chlorin
atom
introduct
electroneg
group
nitro
group
benzen
ring
could
possibl
deactiv
mustard
group
thu
nitrocaphan
synthes
compar
respect
antitumor
activ
toxic
experiment
data
reveal
remark
therapeut
effect
differ
anim
tumor
better
intraperiton
inject
mgkg
produc
inhibit
ehrlich
solid
carcinoma
solid
hepatoma
mice
therapeut
effect
nearli
given
oral
mgkg
rat
bear
jensen
sarcoma
cm
tumor
mass
produc
tumor
regress
major
rat
day
seven
inject
drug
cure
rate
nitrocaphan
ocaphan
use
toler
dose
ocaphan
mgkg
caus
nitrocaphan
mgkg
p
tumor
inhibit
mice
bear
ehrlich
carcinoma
nitrocaphan
mgkg
inhibit
carcinoma
rabbit
inocul
intraocularli
inhibit
caus
ocaphan
drug
prolong
surviv
rabbit
tumor
inocul
intraven
experi
cnitrocaphan
show
radioact
distribut
throughout
mani
intern
organ
oral
administr
highest
content
c
note
kidney
intestin
liver
tumor
lung
normal
rat
biolog
halflif
drug
plasma
min
excret
mainli
urin
fece
total
excret
within
h
clinic
data
demonstr
drug
effect
nasopharyng
carcinoma
malign
lymphoma
lung
cancer
therapeut
efficaci
frequent
observ
carcinoma
squamou
cell
undifferenti
cell
type
use
intraven
oral
local
side
effect
includ
anorexia
vomit
bone
marrow
depress
sever
could
amelior
abolish
symptomat
treatment
sinc
drug
manufactur
use
mani
hospit
varieti
cancer
patient
one
power
alkyl
agent
china
nitrocaphan
includ
list
basic
antitumor
drug
cancer
patient
easi
use
han
report
institut
seri
cyclophosphamid
deriv
synthes
screen
anticanc
activ
among
n
ndi
n
ndiethoxi
carbonyl
phosphoramid
prove
strongest
compound
exhibit
signific
inhibitori
action
yoshida
sarcoma
walker
carcinosarcoma
rat
bear
tumor
cure
complet
clinic
studi
indic
drug
effect
treat
lung
cancer
anaplast
form
breast
cancer
particular
ulcer
form
hodkgin
diseas
could
inhibit
mitosi
hela
cell
differ
cyclophosphamid
china
drug
use
local
treatment
cancer
ulcer
advanc
patient
remark
effect
ethan
propylenediamin
tetraacetylimid
razoxan
frequent
use
cancer
chemotherapi
antimetastasi
activ
order
search
better
drug
ren
simm
synthes
biomolan
ethan
new
compound
found
possess
definit
therapeut
effect
lymphoma
breast
carcinoma
tumor
also
use
treatment
patient
psoriasi
uveiti
probiman
propan
design
analog
bimolan
discov
better
antitumor
action
bimolan
produc
mark
antitumor
action
lewi
lung
carcinoma
melanoma
colon
adenocarcinoma
hepatoma
mice
also
activ
spontan
lymphoma
human
bronchial
adenocarcinoma
heterotranspl
nude
mice
moreov
exhibit
potenti
effect
irradi
sarcoma
mice
show
mutagen
activ
ame
test
clabel
probiman
studi
show
easili
absorb
oral
administr
wide
distribut
major
tissu
probiman
excret
mainli
urin
partli
fece
c
label
central
dioxopiperazin
methyl
morpholin
group
probiman
inject
intraven
mice
bear
lewi
lung
carcinoma
whole
bodi
autoradiographi
drug
broken
least
two
part
central
part
methyl
morpholin
group
central
part
compound
hardli
penetr
barrier
accumul
urinari
bladder
methyl
morpholin
group
reveal
high
affin
tumor
tissu
accumul
spleen
bone
liver
mice
bear
tumor
probiman
could
decreas
serum
sialic
acid
level
thought
relat
antimetastat
effect
longterm
administr
bimolan
incid
acut
leukemia
sever
case
report
thu
biomolan
stop
ren
cai
design
prepar
mani
analog
probiman
among
bi
sobuzoxan
found
best
one
studi
detail
cooper
japanes
colleagu
sobuzoxan
subject
systemat
preclin
clinic
studi
prove
drug
effect
treatment
leukemia
lymphoma
patient
present
sobuzoxan
obtain
approv
japan
clinic
use
product
administ
oral
amelior
toxic
induc
doxorubicin
use
combin
therapi
complexon
sever
metal
inhibit
growth
sarcoma
mice
sever
aminocarboxyl
complexon
antimoni
could
produc
mark
inhibit
anim
tumor
among
test
compound
antimoni
ammonia
triacet
acid
antimoni
sodium
pdta
found
better
therapeut
action
number
experiment
tumor
compound
significantli
prolong
surviv
time
mice
bear
ehrlich
ascit
carcinoma
spindl
cell
sarcoma
obvious
retard
growth
guerin
carcinoma
rat
inhibit
also
exert
therapeut
effect
sarcoma
experiment
result
show
inhibit
four
stage
mitosi
cancer
cell
interphas
cell
show
also
definit
chang
conglutin
structur
nuclear
chromatin
prove
therapeut
effect
close
relat
inhibitori
action
mitot
process
toxicolog
studi
mice
rabbit
monkey
show
sever
side
effect
flatten
twave
ekg
nausea
vomit
decreas
bodi
weight
observ
group
receiv
high
dosag
subcutan
inject
sodium
dimercaptosuccin
balglucosid
bal
cystein
could
produc
signific
protect
action
upon
mice
intox
decreas
mortal
rate
mice
sulfhydryl
drug
could
also
antagon
tumorinhibitori
action
antitumor
effect
could
recur
dose
level
increas
later
recommend
clinic
trial
exhibit
therapeut
effect
patient
gastrointestin
carcinoma
fibrosarcoma
breast
carcinoma
tumor
new
anticanc
drug
approv
china
product
use
mani
hospit
mechanist
studi
reveal
inhibit
significantli
incorpor
zn
tumor
cell
mice
bear
ehrlich
ascit
carcinoma
zinc
chlorid
could
exert
antagonist
action
therapeut
effect
drug
experi
distribut
excret
indic
sb
could
combin
cancer
cell
high
affin
sulfhydryl
compound
sodium
dimercaptosuccin
cystein
decreas
obvious
sb
content
tumor
cell
find
provid
us
new
approach
search
novel
anticanc
agent
unfortun
period
time
due
polit
movement
work
interrupt
work
team
disorgan
well
concern
consid
clinic
use
product
studi
second
gener
drug
discontinu
metal
anticanc
drug
cisplatin
carboplatin
appear
remark
therapeut
efficaci
cancer
patient
caus
great
interest
chemic
medic
research
cisplatin
recogn
one
success
drug
cancer
chemotherapi
late
hu
et
al
xiamen
univers
systemat
investig
antimoni
metal
compound
synthes
mani
deriv
elucid
relationship
sar
also
conduct
collabor
work
russian
scientist
determin
crystal
structur
chemic
analysi
xray
diffract
infrar
ir
spectroscopi
method
absolut
configur
antimoni
chelat
includ
also
studi
hu
point
work
antimoni
chelat
compound
publish
farsight
compar
metal
chelat
agent
design
synthesi
activ
assay
specul
antimoni
prepar
less
toxic
metal
drug
possess
alkyl
activ
differ
mode
action
could
interact
trace
metal
affect
tumor
growth
metastasi
tiekink
review
articl
indic
explor
anticanc
potenti
antimoni
bismuth
compound
well
develop
metalcontain
speci
deserv
research
effort
base
find
toxic
therapeut
effect
action
mechan
seem
us
analog
bright
futur
investig
necessari
simm
compound
found
antitumor
activ
oxalysin
anordrin
cheliensisin
studi
detail
regard
sar
action
mechan
agent
lack
good
clinic
result
serv
lead
compound
studi
taxol
import
anticanc
agent
first
isol
bark
pacif
yew
taxu
brevifolia
wani
et
al
chemic
structur
uniqu
disrupt
action
microtubul
suitabl
clinic
formul
discov
drug
use
wide
treatment
differ
cancer
report
systemat
studi
taxol
isol
taxu
chinensi
conduct
nation
prepar
drug
similar
efficaci
import
taxol
approv
clinic
use
product
recent
year
new
prepar
taxolliposom
prepar
number
laboratori
clinic
data
show
good
therapeut
action
fewer
side
effect
implant
new
sustainedreleas
prepar
invent
hefei
technolog
univers
anhui
provinc
clinic
studi
indic
sustainedreleas
prepar
locat
directli
tumor
mass
increas
prolong
local
drug
concentr
drug
prepar
enhanc
therapeut
action
allevi
side
effect
remark
implant
obtain
sfda
approv
product
new
prepar
frequent
employ
mani
hospit
particular
surgic
oncolog
depart
china
mention
earlier
atra
exert
promin
therapeut
action
acut
promyelocyt
leukemia
new
analog
ethoxycarbophenyl
retinamid
carboxylphenyl
retinamid
could
use
cancer
chemoprevent
agent
treatment
precancer
lesion
leucoplakia
mouth
vulva
cure
rate
patient
squamou
skin
cancer
also
cure
new
drug
well
prepar
discov
number
chines
institut
clinic
hospit
medic
school
pharmaceut
compani
tcmrelat
organ
might
found
elsewher
moleculartarget
anticanc
agent
dna
replic
transcript
chromosom
segreg
critic
cellular
event
cell
properli
prolifer
grow
execut
differ
function
process
doublestrand
dna
becom
entangl
topolog
problem
need
solv
time
effici
manner
dna
topoisomeras
cellular
enzym
respons
problem
topoisomeras
function
via
introduc
transient
break
dna
cleav
singl
doubl
strand
rejoin
broken
end
follow
rotat
passag
strand
topoisomeras
classifi
two
type
type
ii
type
topoisomeras
includ
nuclear
topoisomeras
mitochondri
topoisomeras
topoisomeras
topoisomeras
introduc
singlestrand
break
dna
without
requir
atp
type
ii
topoisomeras
gener
doublestrand
break
dsb
hydrolyz
atp
contain
topoisomeras
ii
subtyp
essenti
mammal
absolut
requir
dna
replic
addit
frequent
hyperactiv
tumor
cell
therefor
target
becom
import
success
strategi
cancer
therapi
camptothecin
inhibitor
use
cancer
therapi
present
wall
wani
isol
pentacycl
alkaloid
camptothecin
c
acuminata
becam
prototyp
modif
optim
came
clinic
use
china
first
camptothecin
deriv
anoth
two
wellknown
camptothecin
deriv
topotecan
irrinotecan
approv
clinic
anticanc
use
japan
us
worldwid
camptothecin
becam
one
import
class
anticanc
drug
clinic
use
extens
use
treatment
variou
solid
tumor
includ
lung
colorect
cancer
crc
howev
current
camptothecin
clinic
use
show
sever
seriou
drawback
includ
unstabl
lacton
revers
interact
sever
toxic
drug
resist
therefor
consider
effort
appli
discoveri
novel
camptothecin
deriv
contrast
inhibitor
lot
inhibitor
use
clinic
cancer
treatment
inhibitor
divid
poison
catalyt
inhibitor
catalyt
inhibitor
inhibit
activ
cleav
dna
strand
enter
clinic
anticanc
use
clinic
use
inhibitor
includ
etoposid
doxorubicin
mitoxantron
poison
characterist
cleav
dna
doubl
strand
increas
coval
complex
inhibitor
primarili
poison
long
firstlin
drug
treatment
variou
solid
tumor
import
compon
mani
therapeut
regimen
contain
moleculartarget
drug
howev
drug
bear
intoler
toxic
especi
bone
marrow
suppress
defect
also
includ
gener
drug
resist
limit
efficaci
metastat
tumor
consequ
increas
interest
search
develop
anticanc
agent
target
human
especi
new
chemic
scaffold
new
mode
action
investig
simm
put
intens
effort
discoveri
new
inhibitor
topoisomeras
primarili
focus
natur
product
section
describ
anticanc
activ
possibl
molecular
mechan
sever
promis
topoisomeras
inhibitor
special
emphasi
uniqu
mode
action
inhibitor
includ
inhibitor
salvicin
gambog
acid
ga
echinosid
inhibitor
chimmitecan
deriv
camptothecin
salvicin
novel
diterpenoid
quinon
compound
figur
structur
modifi
natur
product
lead
isol
chines
medicin
plant
salvia
prioniti
hanc
labiata
plant
use
folk
medicin
antibacteri
antitubercular
antiphlogist
action
salvicin
demonstr
multipletarget
anticanc
drug
candid
primari
cellular
target
salvicin
distinguish
novel
chemic
structur
distinct
profil
anticanc
activ
low
toxic
new
mode
action
promis
pharmaceut
perspect
present
salvicin
undergo
phase
ii
clinic
trial
china
promis
perspect
translat
lifesav
therapeut
option
anticanc
activ
vitro
vivo
salvicin
display
potent
growth
inhibitori
activ
panel
human
tumor
cell
line
vitro
mice
bear
human
tumor
xenograft
salvicin
cytotox
classic
anticanc
drug
etoposid
weaker
vincristin
three
leukemia
cell
line
potent
etoposid
vincristin
solid
tumor
cell
line
notic
salvicin
show
rel
select
anticanc
activ
particularli
gastric
lung
carcinoma
cell
anticanc
effect
salvicin
found
associ
abil
induc
apoptosi
indic
cell
salvicin
possess
signific
antineoplast
activ
murin
sarcoma
lewi
lung
cancer
human
lung
adenocarcinoma
xenograft
consist
result
vitro
studi
salvicin
elicit
signific
inhibit
lung
gastric
adenocarcinoma
includ
xenograft
salvicin
growth
inhibitori
effect
ibc
xenograft
nude
mice
distinguish
activ
multidrugresist
tumor
cell
tumor
multidrugresist
mdr
consid
one
import
impedi
effect
chemotherapi
cancer
mdr
primarili
involv
anticanc
drug
natur
origin
alway
focus
area
develop
new
strategi
circumv
mdr
therefor
especi
noteworthi
salvicin
abl
circumv
mdr
caus
pglycoprotein
pgp
overexpress
salvicin
effect
kill
tumor
cell
overexpress
pgp
mean
resist
factor
much
lower
vincristin
doxorubicin
etoposid
salvicin
induc
similar
level
apoptosi
mdr
parent
cell
promis
activ
mdr
unlik
mdr
modul
inhibit
drug
efflux
pgp
salvicin
downregul
pgp
express
mdr
cell
signific
antimetastat
activ
tumor
metastasi
main
threat
live
patient
cancer
circumst
metastasi
refer
dissemin
cancer
cell
initi
tumor
distant
site
involv
seri
process
includ
loss
adhes
acquisit
cell
motil
extracellular
proteolysi
angiogenesi
salvicin
significantli
reduc
lung
metastat
foci
orthotop
xenograft
without
obvious
affect
primari
tumor
growth
indic
salvicin
possess
promin
inhibit
tumor
metastasi
salvicin
inhibit
distinct
mechan
salvicin
noninterc
inhibitor
differ
classic
inhibitor
mode
action
specif
salvicin
promot
noncoval
bind
shown
inhibit
dna
relig
though
affect
dna
cleavag
moreov
salvicin
shown
bind
atpas
domain
human
high
affin
inhibit
activ
compet
atp
addit
noteworthi
inhibit
salvicin
abrog
glutathion
gsh
reactiv
oxygen
speci
ro
scaveng
suggest
inhibitori
effect
might
due
ro
gener
togeth
salvicin
emerg
novel
inhibitor
distinct
mode
action
ro
gener
competit
bind
atp
pocket
promot
bind
inhibit
dna
relig
salvicin
induc
genespecif
dna
damag
nonselect
dna
damag
induc
dnadamag
agent
main
caus
sever
toxic
side
effect
dnadamag
agent
use
clinic
use
attack
dna
without
select
aspect
salvicin
potenti
advantag
induc
genespecif
dna
damag
tumor
cell
preferenti
damag
occur
promot
region
oncogen
cmyc
obviou
dna
damag
found
region
gene
appear
possibl
dna
damag
within
genom
region
earli
event
could
lead
growth
inhibit
mediat
alter
express
select
prolifer
regulatori
gene
cmyc
activ
transcript
factor
cjun
downregul
express
inhibit
dna
repair
transcript
factor
cjun
involv
extens
pathophysiolog
process
salvicin
found
stimul
cjun
gene
express
inhibit
gene
express
mdr
cell
salvicin
enhanc
level
activ
form
jnk
cjun
rais
dnabind
activ
inhibit
cjun
express
disrupt
enhanc
cjun
pcjun
salvicin
simultan
prevent
reduct
mrna
pgp
protein
level
confirm
cjun
activ
prerequisit
reduct
mrna
pgp
protein
level
salvicin
importantli
downregul
cjun
express
inhibit
apoptosi
cytotox
induc
salvicin
mdr
parent
cell
anoth
studi
reveal
activ
jnk
enzym
respons
phosphoryl
cjun
directli
contribut
suppress
gene
express
clear
molecular
pathway
salvicin
reduc
express
drawn
salvicin
stimul
jnk
phosphoryl
activ
jnk
phosphoryl
serin
cjun
result
increas
transcript
activ
phosphoryl
cjun
promot
express
cjun
thu
increas
cjun
level
furthermor
transcriptionfactor
complex
contain
cjun
bind
consensu
target
element
gene
promot
repress
transcript
lead
reduct
mrna
pgp
express
kill
mdr
tumor
cell
hand
salvicin
inhibit
dnapkdepend
dna
repair
dnapkdepend
dna
repair
abrog
dna
damag
dna
dsb
trigger
apoptosi
cell
kill
repair
broken
dna
gener
reduc
anticanc
activ
dnadamag
agent
enhanc
dna
repair
one
key
element
result
drug
resist
thu
interfer
dna
repair
emerg
new
approach
circumv
tumor
drug
resist
salvicin
significantli
inhibit
dnapkdepend
dna
repair
reduc
kinas
activ
protein
level
catalyt
subunit
dnapk
critic
compon
nonhomolog
end
join
thu
salvicin
bear
interest
characterist
featur
trigger
dna
dsb
inhibit
dna
repair
simultan
possibl
favor
direct
cell
kill
mdr
cell
anoth
characterist
salvicin
salvicin
induc
mdr
persist
induct
combin
onestep
select
salvicineresist
sublin
establish
compar
parent
cell
cell
display
resist
salvicin
averag
resist
antimetabolit
cell
howev
resist
alkyl
agent
platinum
compound
natur
deriv
antineoplast
indic
persist
exposur
salvicin
induc
typic
tumor
multidrugresist
mdr
phenotyp
take
fact
salvicin
overcom
mdr
induc
mdr
togeth
appear
possibl
salvicin
would
effect
mdr
tumor
clinic
tumor
metastasi
one
common
caus
lead
death
salvicin
possess
signific
activ
tumor
metastasi
comparison
gene
express
profil
primari
tumor
lung
metastasi
salvicinetr
untreat
group
reveal
gene
involv
tumor
metastasi
particularli
close
relat
cell
adhes
motil
obvious
downregul
includ
fibronectin
integrin
integrin
integrin
fak
paxillin
rhoc
salvicin
shown
downregul
rhoc
mrna
protein
level
inhibit
stress
fiber
format
invas
cell
block
transloc
rhoa
rhoc
cytosol
membran
addit
salvicin
specif
inhibit
adhes
human
breast
cancer
cell
fibronectin
collagen
fibronectindepend
format
focal
adhes
actin
stress
fiber
also
inhibit
salvicin
salvicin
downregul
integrin
ligand
affin
cluster
signal
via
dephosphoryl
focal
adhes
kinas
paxillin
moreov
salvicin
induc
extracellular
signalregul
kinas
erk
mitogenactiv
protein
kinas
mapk
activ
salvicin
also
promot
product
ro
contribut
salvicineinduc
activ
erk
mapk
salvicin
gener
ro
inactiv
integrin
function
result
cell
adhes
inhibit
collect
antimetastat
activ
salvicin
close
relat
rhodepend
signal
pathway
inhibitori
effect
salvicin
system
length
telomer
shorten
cell
divis
limit
cell
fix
number
divis
telomeras
abl
maintain
length
telomer
import
cell
divid
unlimitedli
telomeras
hyperactiv
tumor
cell
critic
immort
tumor
cell
thu
telomer
telomeras
recogn
potenti
anticanc
target
salvicineinduc
downregul
telomeras
activ
cell
preced
decreas
express
telomeras
catalyt
subunit
htert
telomeraseassoci
protein
mrna
level
protein
phosphatas
inhibitor
okada
acid
prevent
downregul
telomeras
activ
salvicin
signific
increas
protein
phosphatas
activ
induc
salvicin
treatment
block
complet
okada
acid
specif
inhibitor
zdevdfmk
revers
decreas
telomeras
activ
increas
activ
cell
expos
salvicin
thu
salvicineinduc
declin
telomeras
activ
may
primarili
due
dephosphoryl
telomeras
compon
mediat
activ
result
also
confirm
solid
tumor
cell
line
salvicin
demonstr
induc
cell
cycleindepend
telomer
eros
independ
inhibit
telomeras
activ
depend
disrupt
telomer
repeat
bind
factor
salvicin
induc
telomer
dna
damag
telomer
eros
lung
carcinoma
cell
independ
cell
cycl
salvicin
downregul
protein
level
also
imped
bind
overexpress
fulllength
gene
transfect
smallinterf
rna
protein
confirm
protect
telomer
genom
dna
salvicineelicit
event
addit
noteworthi
although
ataxiatelangiectasiamut
atm
atmand
atr
kinas
respond
salvicineinduc
dna
damag
atr
essenti
telomer
eros
thu
activ
atr
augment
salvicinetrigg
disrupt
wherea
reduct
turn
enhanc
atr
function
preclin
phase
clinic
studi
reveal
salvicin
caus
doselimit
toxic
seriou
bone
marrow
suppress
differenti
firstlin
clinic
use
inhibitor
major
toxic
salvicin
belong
includ
leukopenia
neutropenia
elev
transaminas
nausea
vomit
mucos
sweat
cough
forth
irrevers
toxic
observ
drugrel
death
found
salvicin
reveal
sever
uniqu
featur
includ
novel
chemic
structur
distinct
profil
anticanc
activ
new
mode
action
low
toxic
featur
make
distinguish
multipletarget
anticanc
drug
candid
primari
cellular
target
figur
import
question
mechan
action
salvicin
remain
clarifi
exampl
salvicin
activ
cjun
inhibit
dnapk
rhoc
intrins
relationship
link
activ
anticanc
antimetastasi
mdr
circumvent
activ
salvicin
independ
insepar
answer
question
could
greatli
help
acceler
undergo
phase
ii
clinic
trial
guid
potenti
clinic
use
futur
naphthalimid
analog
amonafid
naphthalimid
deriv
although
select
exploratori
clinic
trial
potent
anticanc
activ
long
challeng
unpredict
side
effect
clinic
studi
found
amonafid
extens
metabol
nacetylamonafid
via
nacetyl
nacetyltransferas
metabolit
caus
highvari
unpredict
toxic
interindividu
differ
nacetyl
greatli
obstruct
clinic
develop
scientist
east
china
univers
scienc
technolog
shanghai
peopl
republ
china
synthes
def
substitut
nh
naphthyl
figur
salvicin
multipletarget
anticanc
drug
candid
primari
anticanc
target
symbol
promot
inhibit
abbrevi
topoisomeras
ii
ro
reactiv
oxygen
speci
dnapk
dnadepend
protein
kinas
nhej
nonhomolog
end
join
pgp
pglycoprotein
mdr
multidrug
resist
erk
extracellular
signalregul
kinas
mapk
mitogenactiv
protein
kinas
protein
phosphatas
htert
human
telomeras
catalyt
subunit
atr
atmand
telomer
repeat
bind
factor
heterocycl
group
amonafid
addit
introduct
thiol
group
figur
substitut
elimin
potenti
toxic
threat
amonafid
nh
group
posit
cytotox
parent
compound
amonafid
human
tumor
cell
line
also
effect
mdr
cell
importantli
inhibit
tumor
growth
mice
implant
sarcoma
hepatoma
mechanist
studi
show
function
poison
via
bind
atpas
domain
human
use
catalyt
inhibitor
aclarubicin
atmatr
kinas
inhibitor
caffein
cell
shown
dna
dsb
tumor
cell
cycl
arrest
apoptosi
manner
induc
arrest
via
atmactiv
pathway
trigger
phosphoryl
dnadamag
sensor
atm
respond
dna
dsb
inhibit
atm
use
pharmacolog
inhibitor
caffein
specif
small
interfer
rna
sirna
rescu
arrest
elicit
indic
atmdepend
manner
naphthalimidedriven
arrest
furthermor
deplet
correspond
sirna
revers
amonafidetrigg
arrest
moreov
analog
phosphoryl
persist
atmdepend
manner
therefor
well
amonafid
could
preferenti
employ
could
account
differenti
phosphoryl
atm
time
demonstr
trigger
time
concentrationdepend
reduct
unrel
mrna
level
degrad
proteasom
inhibitor
lactacystin
prevent
declin
induc
accompani
signific
accumul
ubiquitin
protein
indic
involv
pathway
also
result
loss
function
site
specif
mutat
phosphoryl
site
protein
reduct
demonstr
associ
apoptot
induct
cell
kill
thu
novel
inhibitor
induc
degrad
via
pathway
impair
function
thu
contribut
anticanc
activ
gambog
acid
ga
figur
natur
product
isol
ambog
resin
garcinia
hurburyi
tree
approv
test
clinic
trial
wide
spectrum
antitumor
drug
undergo
phase
ii
clinic
trial
china
ga
shown
exert
antitumor
effect
via
induct
apoptosi
depend
caspas
independ
cell
cycl
breast
cancer
specif
act
key
executor
gainduc
apoptosi
ga
target
transferrin
receptor
trigger
rapid
apoptosi
tumor
ga
also
reveal
downregul
telomeras
directli
interact
cmyc
human
hepatoma
lung
cancer
cell
reduc
kinas
activ
inhibit
activ
nfkb
target
microtubulinassoci
protein
stathmin
howev
target
activ
ga
seem
hard
account
nonselect
anticanc
activ
recent
identifi
primari
cellular
target
ga
ga
significantli
inhibit
catalyt
activ
although
trap
stabil
coval
cleavag
complex
ga
inhibit
dna
cleavag
atp
hydrolysi
downregul
prevent
gainduc
apoptosi
restor
cell
prolifer
moreov
ga
directli
bind
atpas
domain
may
share
common
bind
site
atp
ga
also
inhibit
dna
cleavag
modul
activ
poison
find
target
ga
give
deep
insight
molecular
anticanc
mechan
could
guid
undergo
clinic
evalu
reduc
accumul
driven
hypoxia
growth
factor
human
cancer
cell
howev
affect
degrad
protein
level
mrna
contrast
appar
inhibit
constitut
induc
activ
akt
mapk
pathway
moreov
abrog
increas
vegf
mrna
vegf
protein
secret
also
lower
basal
level
vegf
secret
therefor
import
featur
emerg
reduc
constitut
vegf
secret
concurr
antagon
induc
vegf
secret
consequ
disrupt
tube
format
human
umbil
vein
endotheli
cell
huvec
stimul
hypoxia
lowconcentr
serum
serum
normoxia
inhibit
huvec
migrat
normoxia
also
prevent
microvessel
outgrowth
rat
aortic
ring
therebi
elicit
potent
antiangiogenesi
differ
condit
use
specif
smallinterf
rna
target
cell
reveal
affect
accumul
huvec
tube
format
irrelev
inhibit
significantli
subcytotox
concentr
reduc
constitut
induc
accumul
vegf
secret
via
mapk
pathway
elicit
antiangiogenesi
independ
inhibit
cytotox
concentr
therefor
dual
target
antiangiogenesi
inhibit
separ
manner
uniqu
featur
might
offer
therapeut
benefit
potenti
clinic
set
figur
potenti
novelti
divers
chemic
structur
marinederiv
natur
product
persist
drive
search
new
type
anticanc
agent
result
discoveri
sever
drug
candid
uniqu
structur
mechan
action
includ
ecteinascidin
squalamin
psammaplin
clinic
trial
display
excel
therapeut
effect
treat
recurr
refractori
cancer
echinosid
figur
antifung
marinederiv
saponin
isol
sea
cucumb
echinosid
show
potent
antitumor
activ
inhibit
growth
sarcoma
hepatoma
standard
mous
model
human
prostat
carcinoma
xenograft
nude
mous
model
echinosid
dna
noninterc
inhibitor
reveal
uniqu
characterist
inhibit
noncoval
bind
dna
compet
dna
dnabind
domain
enzym
interf
predominantli
prestrandpassag
cleavagerelig
equilibrium
poststrandpassag
one
featur
distinguish
echinosid
known
inhibitor
etoposid
doxorubicin
moreov
echinosid
induc
dna
dsb
top
manner
togeth
new
chemic
entiti
potent
vitro
vivo
antitumor
activ
uniqu
action
mode
echinosid
make
new
prototyp
modif
optim
develop
new
anticanc
drug
chimmitecan
novel
small
alkyl
substitut
camptothecin
figur
potent
inhibit
outstand
anticanc
activ
vitro
vivo
salient
antimdr
activ
good
stabil
human
serum
albumin
improv
solubl
avail
featur
favor
promis
therapeut
potenti
clinic
set
anticanc
activ
chimmitecan
exert
potent
vitro
antitumor
activ
wide
varieti
human
tumor
cell
line
origin
differ
tissu
includ
leukemia
lung
gastric
hepatocellular
colon
breast
ovarian
cervic
cancer
compar
studi
reveal
enhanc
anticanc
potenc
chimmitecan
averag
ic
human
tumor
cell
line
nm
significantli
lower
topotecan
nm
nm
chimmitecan
display
similar
select
anticanc
effect
topotecan
notabl
chimmitecan
effect
three
pair
mdr
tumor
cell
line
topotecan
indic
potenti
antimdr
activ
addit
cytotox
chimmitecan
unaffect
human
serum
albumin
chimmitecan
test
vivo
anticanc
activ
nude
mice
use
human
tumor
cell
line
differ
tissu
origin
includ
lung
gastric
hepatocellular
colon
pancreat
cancer
result
show
human
cancer
lung
colon
pancrea
highli
sensit
chimmitecan
evidenc
almost
total
disappear
tumor
xenograft
nude
mice
treat
chimmitecan
gastric
hepatocellular
cancer
display
medium
sensit
molecular
mechan
camptothecin
chimmitecan
also
produc
anticanc
effect
inhibit
catalyt
activ
trap
stabil
coval
complex
nanomolar
level
chimmitecan
caus
impress
dna
damag
arrest
apoptosi
human
leukemia
colon
cancer
cell
chimmitecan
well
camptothecin
found
induc
repair
dsb
human
colon
cancer
cell
cellular
dispos
dsb
reflect
progress
dispers
foci
reduct
comet
tail
dynam
activ
homolog
recombin
hr
repair
revers
arrest
process
differenti
kinet
activ
character
progress
increas
phosphoryl
h
degrad
disappear
phosphoryl
h
drug
remov
use
rna
interfer
show
essenti
arrest
wherea
mainli
requir
hr
repair
cpttreat
cell
moreov
rather
predomin
control
cell
surviv
model
differenti
role
regul
hr
repair
arrest
also
confirm
colon
cancer
cell
data
provid
critic
evid
explor
checkpoint
modul
especi
inhibit
therapeut
strategi
combin
chimmitecan
camptothecin
clinic
success
protein
tyrosinekinas
ptk
inhibitor
gleevec
establish
mileston
anticanc
therapi
sinc
lot
moleculartarget
anticanc
agent
specif
ptk
includ
epiderm
growth
factor
receptor
egfr
human
epiderm
growth
factor
receptor
plateletderiv
growth
factor
receptor
pdgfr
vascular
endotheli
growth
factor
receptor
vegfr
becom
compon
standard
regimen
anticanc
combin
therapi
among
inhibitor
tumor
angiogenesi
import
repres
angiogenesi
play
critic
role
tumor
progress
particularli
growth
metastasi
solid
tumor
avascular
tumor
rare
exceed
mm
vascular
tumor
grow
rapidli
nearli
exponenti
moreov
vascular
densiti
tumor
close
associ
metastat
potenti
thu
malign
inhibit
tumor
angiogenesi
one
import
strategi
cancer
therapi
sever
angiogenesi
inhibitor
includ
bevacizumab
avastin
sorafenib
nexavar
sunitinib
sutent
appli
success
clinic
therapi
solid
tumor
combin
chemotherapi
howev
current
antiangiogen
agent
face
challeng
tumor
drug
resist
includ
evas
intrins
resist
therefor
new
inhibitor
angiogenesi
particularli
new
chemic
skeleton
new
mechan
action
necessari
develop
compound
deriv
natur
product
gener
characterist
divers
chemic
structur
possibl
new
mode
action
mind
chines
investig
taken
advantag
rich
natur
resourc
order
discov
new
type
antiangiogen
agent
lot
natur
compound
distinguish
appar
antiangiogen
activ
new
mechan
action
section
describ
sever
repres
compound
includ
pseudolar
acid
b
pab
oligomannurar
sulfat
philinopsid
e
pe
grateloupia
longifolia
polysaccharid
glp
current
cellular
signal
kinasetarget
anticanc
agent
specif
singl
target
gener
rel
low
therapeut
effect
predispos
tumor
drug
resist
therefor
increas
interest
agent
target
specif
signal
cascad
multipl
molecular
target
addit
effort
put
discoveri
agent
circumv
tumor
resist
current
moleculartarget
anticanc
therapeut
follow
section
briefli
introduc
three
repres
agent
includ
cascad
inhibitor
multitarget
ptk
inhibitor
marinederiv
oligosaccharid
sulfat
mdo
new
egfr
inhibitor
bb
addit
anoth
two
new
cellular
signal
kinasetarget
anticanc
compound
also
display
promin
preclin
anticanc
activ
deriv
rapamycin
novel
specif
inhibitor
mtor
improv
water
solubl
vivo
anticanc
activ
hand
synthet
multitarget
ptk
inhibitor
target
kdr
pdgfr
ckit
ic
nanomolar
rang
potent
vivo
anticanc
activ
commerci
avail
multitarget
ptk
inhibitor
sorafenib
sutent
pseudolar
acid
b
pab
figur
first
isol
scientist
simm
root
bark
pseudolarix
kaempferi
gorden
use
antifung
agent
agent
caus
earli
termin
pregnanc
folk
medicin
china
recent
pab
prove
possess
potent
anticanc
activ
target
microtubulin
neoangiogenesi
detail
studi
show
hydrophob
group
doubl
bond
acyloxi
oac
side
chain
conjug
doubl
bond
hydrophil
termin
group
essenti
anticanc
activ
pab
inhibit
neoangiogenesi
pab
reveal
promin
antiangiogenesi
activ
evidenc
reduc
vegfstimul
huvec
migrat
tube
format
huvec
neovascular
chicken
chorioallanto
membran
mechan
involv
inhibit
angiogenesi
potenti
human
endotheli
cell
downregul
level
protein
promot
proteasomemedi
degrad
human
tumor
cell
hypoxiainduc
factor
initi
factor
neoangiogenesi
becom
attract
anticanc
target
pab
display
potent
vitro
antiangiogen
activ
shown
inhibit
vegfstimul
prolifer
migrat
fetal
bovin
serumstimul
tube
format
human
umbil
vascular
endotheli
cell
concentrationdepend
manner
moreov
pab
nmol
per
egg
significantli
suppress
vivo
angiogenesi
cam
assay
hand
pab
abrog
hypoxiainduc
vegf
secret
cell
via
reduc
protein
select
proteasom
inhibitor
complet
revers
reduct
protein
pabtreat
cell
conclus
pab
display
dual
antiangiogen
activ
directli
inhibit
endotheli
cell
abrog
paracrin
stimul
vegf
tumor
cell
due
reduc
protein
promot
proteasomemedi
degrad
cell
potenti
clinic
relev
hand
antiangiogen
activ
pab
may
also
associ
abil
inhibit
mapkand
aktdriven
antiapotot
aq
signal
thu
antagon
antiapoptot
effect
vegf
pab
suppress
polymer
microtubulin
via
bind
colchicin
site
one
promin
characterist
pab
result
dramat
arrest
follow
apoptosi
either
hmec
tumor
cell
effect
pab
directli
subsequ
disrupt
cellular
tubulin
thu
interfer
mitot
spindl
assembl
effect
pab
shown
suppress
polymer
microtubulin
direct
interact
colchicinebind
site
tubulin
find
provid
cancer
therapi
novel
chemic
class
target
colchicinebind
site
tubulin
heparanas
mammalian
endohdglucuronidas
capabl
partial
depolymer
heparan
sulfat
chain
limit
number
site
thought
help
promot
cancer
invas
metastasi
heparanas
also
tightli
involv
angiogenesi
act
releas
heparan
heparinbind
angiogen
factor
basic
fibroblast
growth
factor
bfgf
possibl
endotheli
cell
growth
factor
basement
membran
extracellular
matrix
thu
perhap
unsurpris
heparanas
express
level
close
correl
metastat
angiogen
potenti
tumor
cell
involv
develop
metastasi
malign
tumor
heparanas
recent
becom
attract
target
treatment
highli
malign
tumor
oligomannurar
sulfat
figur
newli
semisynthes
structur
novel
sulfat
oligosaccharid
deriv
marin
oligomannurar
block
found
new
inhibitor
heparanas
significantli
inhibit
tumor
growth
angiogenesi
metastasi
abolish
heparanasedriven
invas
suppress
releas
heparan
sequest
basic
fibroblast
growth
factor
bfgf
extracellular
matrix
subsequ
angiogenesi
moreov
inactiv
bfgfinduc
bfgf
receptor
phosphoryl
block
bfgftrigger
angiogen
event
directli
bind
bfgf
hand
combat
heparanas
activ
via
bind
kkdc
qplk
domain
heparanas
molecul
interact
competit
inhibit
lowmolecularweight
heparin
glycosaminoglycan
thu
seem
inhibit
heparanas
activ
act
competit
inhibitor
heparan
sulfat
conclus
inhibit
major
heparanas
activ
simultan
act
substrat
mimet
competit
inhibitor
heparan
sulfat
collect
contribut
anticanc
antimetastasi
antiangiogenesi
activ
philinopsid
e
marinederiv
cancer
therapeut
intens
investig
novel
chemic
skeleton
uniqu
anticanc
potenti
trabectedin
yond
tropic
seasquirt
first
marin
drug
approv
cancer
therapi
softtissu
sarcoma
european
union
sever
marin
natur
product
taken
clinic
trial
pe
figur
isol
sea
cucumb
pentacta
quadrangulari
elicit
potent
antiangiogenesi
antitumor
activ
uniqu
molecular
mechan
pe
specif
interact
extracellular
domain
kdr
distinct
convent
smallmolecul
inhibitor
target
cytoplasm
kinas
domain
block
interact
vegf
downstream
signal
molecul
pe
also
markedli
suppress
alpha
v
beta
integrindriven
downstream
signal
result
disturb
physic
interact
kdr
alpha
v
beta
integrin
hmec
follow
disrupt
actin
cytoskeleton
organ
decreas
cell
adhes
vitronectin
find
substanti
pe
unrecogn
therapeut
class
tumor
angiogenesi
importantli
reveal
therapeut
potenti
angiogenesi
cancer
develop
via
target
interact
grateloupia
longifolia
polysaccharid
glp
anoth
marin
natur
product
new
type
polysaccharid
isol
alga
g
longifolia
glp
inhibit
cell
prolifer
migrat
tube
format
cell
reduc
cam
neovascular
result
obviou
vitro
vivo
antiangiogenesi
effect
howev
antiangiogenesi
effect
glp
associ
classic
signal
contrast
glp
significantli
decreas
tissu
factor
mrna
protein
level
suggest
glp
inhibit
angiogenesi
downregul
express
tissu
factor
cascad
inhibitor
hybrid
alphamethylenegammalacton
indol
compound
figur
novel
dual
inhibitor
axi
tubulin
polymer
possess
potent
activ
pathway
one
hand
abrog
egfactiv
signal
cascad
akt
transloc
cellular
membran
human
tumor
cell
inhibit
mtor
minim
affect
test
kinas
notabl
complet
imped
hyperphosphoryl
akt
feedback
inhibit
mtor
rapamycin
hand
arrest
cell
phase
phase
distinct
compound
target
pathway
unexpect
phenomenon
result
fact
inhibit
tubulin
polymer
via
bind
colchicinebind
site
tubulin
molecular
model
support
conclus
concurr
target
pathway
tubulin
reveal
potenti
bind
kinas
domain
subunit
mtor
share
similar
hydrophob
interact
colchicin
complex
tubulin
induc
rapid
apoptosi
tumor
cell
reflect
synerg
block
signal
inhibit
tubulin
cytoskeleton
final
exert
potent
antiprolif
activ
panel
tumor
cell
origin
differ
tissu
type
includ
drugresist
cell
nude
mice
bear
human
tumor
xenograft
collect
target
signal
microtubul
cytoskeleton
combinatori
contribut
antitumor
activ
provid
new
clue
anticanc
drug
design
develop
new
synthet
quinonazolin
deriv
bb
n
propoxi
figur
select
egfr
inhibitor
bb
select
inhibit
egfr
ic
valu
nm
least
potent
suppress
test
receptor
tyrosin
kinas
rtk
consequ
bb
effect
inhibit
autophosphoryl
egfstimul
egfr
phosphoryl
key
downstream
signal
molecul
erk
akt
cell
bb
suppress
egfstimul
prolifer
cell
also
inhibit
egfindepend
prolifer
variou
tumor
cell
bb
also
exhibit
antiangiogenesi
activ
evidenc
antagon
egfinduc
migrat
vitro
block
tube
format
inhibit
microvessel
sprout
rat
aortic
ring
importantli
bb
promin
inhibit
vivo
tumorigenesi
cell
specif
driven
activationmut
egfr
gene
reduc
number
microvessel
xenograft
therefor
bb
could
promis
egfrtarget
anticanc
candid
novel
mdo
figur
multitarget
ptk
inhibitor
inhibit
variou
rtk
nonreceptor
tyrosin
kinas
nrtk
enzymat
level
mdo
suppress
rtk
includ
egfr
vegfr
pdgfr
ckit
nrtk
csrc
minim
impact
consist
mdo
inhibit
phosphoryl
ptk
exemplifi
egfr
downstream
molecul
akt
cellular
level
mdo
suppress
ptk
uniqu
atpcompetit
mode
action
via
directli
bind
residu
entranc
rather
atpbind
pocket
consequ
mdo
exert
excel
antiangiogen
activ
reveal
inhibit
prolifer
tube
format
hmec
arrest
microvessel
outgrowth
rat
aortic
ring
hinder
neovascular
chick
allanto
membran
collect
new
multitarget
ptk
inhibitor
novel
uniqu
scaffold
mdo
could
promis
agent
evalu
ptkassoci
cancer
therapi
evalu
sever
seri
deriv
rtk
play
crucial
role
signal
transduct
pathway
regul
cell
differenti
prolifer
overexpress
certain
growth
factor
receptor
kinas
strongli
associ
carcinogenesi
epiderm
growth
factor
receptor
belong
erbb
receptor
famili
kda
glycoprotein
contain
extracellular
ligandbind
domain
transmembran
region
intracellular
domain
kinas
activ
strong
correl
found
solid
tumor
high
level
egfr
poor
prognosi
thu
egfr
attract
target
design
develop
compound
specif
bind
receptor
inhibit
tyrosinekinas
tk
activ
signal
transduct
pathway
cancer
cell
varieti
approach
use
target
egfr
famili
member
popular
two
explor
extens
cancer
chemotherapi
cancer
overexpress
egfr
famili
receptor
block
ligand
bind
extracellular
domain
human
monoclon
antibodi
use
smallmolecul
inhibitor
interact
atpbind
site
promis
smallmolecul
inhibitor
egfr
kinas
current
sever
scaffold
includ
quinazolin
pyridopyrimidin
benzamid
indolinon
pyrrolotriazin
other
deriv
exhibit
ic
valu
subnanomolar
rang
enzymat
assay
figur
includ
exampl
seri
current
approv
drug
clinic
trial
despit
high
potenc
prolong
inhibit
egfr
function
report
revers
inhibitor
high
intracellular
concentr
atp
make
difficult
inhibitor
reach
suffici
high
concentr
vivo
fulli
shut
egfstimul
signal
transduct
long
period
research
group
therefor
develop
irrevers
inhibitor
base
phenylamino
quinazolin
form
coval
bond
cystein
activ
site
receptor
michael
addit
reaction
furthermor
although
egfr
inhibitor
exhibit
cur
effect
nonsmal
cell
lung
cancer
patient
side
effect
agent
sequenti
found
cutan
effect
therebi
prompt
research
discov
novel
egfr
inhibitor
without
seriou
side
effect
recent
novel
framework
identifi
use
structurebas
virtual
screen
approach
base
crystal
structur
conjunct
chemic
synthesi
bioassay
present
li
cowork
crystal
structur
egfrtk
complex
pdb
entri
recov
brookhaven
protein
data
bank
use
target
virtual
screen
databas
dock
program
kuntz
group
san
francisco
ca
usa
employ
primari
screen
conform
flexibl
compound
databas
consid
dock
search
three
thousand
molecul
highest
score
obtain
dock
search
rescor
use
consensu
score
method
cscore
molecul
cscore
reevalu
pharmacophor
model
egfr
inhibitor
final
compound
distinguish
purchas
bioassay
basi
virtual
screen
flow
among
compound
biosensor
ru
compound
concentr
depend
collect
data
indic
compound
includ
compound
bind
egfr
vitro
bind
affin
egfr
submicroor
micromolar
rang
k
mmoll
compound
figur
bear
higher
bind
affin
egfr
determin
surfac
plasmon
reson
spr
technolog
use
lead
compound
design
new
egfr
inhibitor
chemic
structur
bind
affin
compound
shown
figur
kept
common
moieti
compound
n
thiourea
framework
three
region
two
molecul
select
perform
chemic
modif
suitabl
provid
expedi
signific
sar
inform
improv
inhibitori
activ
substitu
b
n
phenyl
ring
c
npyridinylmethyl
side
chain
figur
first
variou
steric
electron
group
use
substitut
posit
ring
region
obtain
analog
second
compound
design
maintain
region
br
substitu
replac
group
region
b
electron
hydrophob
substitut
aryl
group
final
eight
compound
achiev
replac
pyridinylmethyl
moieti
region
c
electron
hydrophob
group
naryl
acetamid
react
start
materi
reflux
phosphoryl
chlorid
n
ndimethylformamid
dmf
afford
convert
correspond
reflux
hydrochlor
acid
afterward
aldehyd
condens
variou
primari
amin
ethanol
reduc
nabh
give
secondari
amin
target
compound
obtain
nacyl
secondari
amin
use
substitut
isothiocyan
room
temperatur
egfr
kinas
inhibitori
activ
design
compound
evalu
use
kinas
autophosphoryl
assay
elisa
disappointingli
compound
display
low
inhibit
autophosphoryl
egfr
kinas
concentr
enzymat
activ
compound
consist
correl
sprbind
affin
reason
may
protein
immobil
sensor
chip
spr
assay
affect
conform
flexibl
protein
compound
good
binder
moder
inhibitor
egfr
accordingli
effect
compound
tumor
cell
activ
cell
growth
inhibitori
activ
cell
inhibitor
determin
result
indic
six
compound
show
potent
inhibitori
influenc
viabil
remark
inhibitori
activ
compound
increas
approxim
time
compound
encourag
result
prove
valid
chemic
modif
accord
result
noteworthi
conclus
could
drawn
follow
quinolin
ring
region
favor
maintain
activ
especi
within
small
group
phenyl
ring
region
b
substanti
improv
potenc
replac
phenyl
ring
larg
naphthanyl
ring
toler
nearli
lead
loss
activ
introduct
cycloalkyl
moieti
region
c
improv
activ
distinctli
compar
hetero
aromat
moieti
inconsist
enzym
activ
cellular
effici
explain
tent
base
dock
simul
moreov
model
egfr
obtain
crystal
structur
compar
compound
egfr
gener
base
dock
simul
figur
figur
show
nitrogen
quinazolin
accept
hydrogen
bond
hbond
amid
nitrogen
simultan
quinazolin
nitrogen
form
strong
hbond
interact
side
chain
water
molecul
bridg
import
maintain
inhibitori
activ
wherea
quinolin
moieti
form
hbond
backbon
carbonyl
group
phenyl
ring
b
region
piperidin
ring
c
region
form
weak
hydrophob
interact
residu
figur
differ
format
hbond
inhibitor
kinas
domain
may
affect
inhibit
egfr
kinas
activ
indic
design
compound
might
interact
multipl
protein
involv
egfr
signal
pathway
target
tk
thu
lead
promis
antiprolifer
effect
cell
line
core
wellknown
pharmacophor
develop
ptk
inhibitor
figur
sun
et
al
develop
extens
sar
analog
suggest
inhibitori
activ
select
compound
particular
ptk
depend
substitu
core
especi
posit
adopt
z
configur
substitut
potent
select
inhibitor
fgf
tk
howev
compound
e
configur
substitut
benzylidenyl
show
fairli
good
potenc
inhibit
egfrtk
xray
crystal
structur
fgfr
tk
complex
methylen
reveal
core
occupi
adenin
pocket
atpbind
site
tk
substitut
group
posit
bound
hydrophob
pocket
atpbind
site
figur
z
configur
select
inhibitor
fgfr
vegfr
caught
research
attent
particular
biolog
activ
deriv
interest
explor
whether
would
enhanc
interact
compound
tk
increas
antitumor
activ
introduc
group
posit
accordingli
novel
class
deriv
synthes
li
cowork
inhibitori
activ
egfr
fgfr
vegfr
pdgfr
determin
acetonedicarboxyl
use
start
materi
gener
react
tbutyl
acetoacet
classic
knorr
synthesi
produc
substitut
pyrrol
respect
pyrrol
hydrogen
decarboxyl
treat
vilsmeier
formyl
condit
give
commerci
avail
prepar
bromin
nitrat
respect
afford
hydrolysi
prepar
chloroacetyl
aminosulfonyl
substitut
aminosulfonyl
obtain
amid
chlorosulfonyl
prepar
sulfonyl
chlorosulfon
acid
target
compound
synthes
condens
pyrrol
aldehyd
presenc
piperidin
total
new
compound
design
synthes
absolut
configur
final
confirm
xray
structur
analysi
yellow
needl
singl
crystal
obtain
slow
evapor
dilut
solut
etohh
xray
crystal
structur
shown
figur
pyrrol
ring
carbonyl
opposit
side
doubl
bond
indic
e
isomer
superposit
autodock
predict
conform
xray
structur
shown
figur
root
mean
squar
deviat
two
conform
major
deviat
flexibl
moieti
ch
co
ch
ch
indic
bioactiv
conform
similar
crystal
structur
disappointingli
compound
display
low
moder
inhibit
activ
egfr
fgfr
vegfr
pdgfr
concentr
extent
compound
exhibit
better
abil
inhibit
egfr
vegfr
kinas
percent
inhibit
fgfr
pdgfr
kinas
howev
cellular
assay
turn
encourag
tabl
four
human
carcinoma
cell
line
adpkd
chosen
cell
prolifer
assay
result
indic
compound
show
promis
antiprolifer
activ
percent
inhibit
rate
tabl
remark
show
fairli
good
activ
adpkd
ic
respect
bromin
nitrat
posit
core
increas
potenc
inconsist
enzym
activ
cellular
effici
could
impli
new
type
compound
might
inhibit
multipl
key
protein
involv
egfr
vegfr
signal
pathway
target
tk
thu
lead
signific
antiprolifer
effect
egfrdepend
tumor
cell
line
highli
relev
overexpress
egfr
vegfr
kinas
definit
mechan
still
studi
compound
dock
activ
site
egfrtk
use
autodock
predict
bioactiv
conform
shown
figur
atpbind
pocket
egfr
consist
bind
pocket
divid
three
region
includ
two
hydrophob
region
adenin
region
adenin
region
mainli
compris
hydrophob
region
shape
locat
deep
insid
atpbind
pocket
hydrophob
region
ii
mainli
compris
form
one
hydrogen
bond
six
hydrophob
interact
figur
intramolecular
hydrogen
bond
n
atom
pyrrol
ring
carboxyl
atom
core
respons
z
isomer
form
figur
chang
ring
ring
distanc
two
atom
lengthen
introduct
methyl
group
posit
pyrrol
ring
avoid
intramolecular
hydrogen
bond
format
figur
show
interact
model
compound
egfr
core
compound
occupi
adenin
pocket
egfr
pyrrol
moieti
lie
hydrophob
region
compound
form
three
hydrogen
bond
eight
hydrophob
interact
bind
model
similar
tarceva
egfr
quinazolin
anilino
moieti
tarceva
also
occupi
adenin
pocket
hydrophob
region
respect
hydrogen
bond
hydrophob
interact
pair
egfr
egfr
provid
promis
new
templat
develop
antitumor
agent
crystal
structur
indic
nitrogen
atom
locat
posit
quinazolin
inhibitor
import
featur
need
good
activ
nitrogen
atom
could
interact
water
molecul
water
molecul
could
serv
bridg
drug
enzym
replac
atom
carbon
lead
signific
loss
abil
compound
inhibit
enzym
accord
wissner
et
al
remov
replac
nitrogen
atom
carbon
atom
attach
cyano
group
seri
synthes
li
cowork
exhibit
signific
abil
inhibit
egfr
kinas
point
chen
et
al
indirect
watermedi
hydrogen
bond
inhibitor
protein
good
reason
attempt
build
space
occupi
water
molecul
success
wissner
et
al
indic
space
due
remov
water
molecul
bound
could
accommod
small
group
basi
consider
seri
novel
deriv
design
cyano
group
posit
replac
nitro
group
effici
facil
synthesi
approach
develop
prepar
varieti
deriv
variou
substitu
begin
commerci
avail
isovanillin
vanillin
benzyl
benzyl
bromid
gave
aldehyd
good
yield
treatment
aldehyd
fume
nitric
acid
furnish
select
nitrat
product
convert
correspond
onitrobenzo
acid
reflux
kmno
afterward
nitro
group
reduc
condens
nitromethan
follow
thermal
cycliz
reflux
aceticanhydrid
give
quinolin
quinolin
convert
good
yield
correspond
chloroquinolin
reflux
excess
pocl
reflux
solut
chloroquinolin
substitut
anilin
deriv
dmf
gener
desir
final
product
good
yield
inhibit
egfr
activ
compound
synthes
evalu
analyz
sulforhodamin
b
srb
sigma
assay
inhibitori
activ
toward
human
epidermoid
carcinoma
breast
cancer
cell
cell
known
overexpress
egfr
lead
continu
activ
egfr
pathway
involv
cell
prolifer
primari
assay
percent
inhibit
compound
concentr
measur
biolog
result
inhibitor
shown
tabl
due
earlier
work
research
group
inhibitor
egfr
establish
metasubstitut
electronwithdraw
group
anilin
moieti
compat
good
activ
featur
retain
initi
compound
initi
compound
attach
ethynyl
group
exhibit
potenti
inhibit
activ
toward
cell
line
inhibit
concentr
replac
ethynyl
group
bromoatom
improv
inhibit
activ
substitut
bromoatom
chloroatom
fluoroatom
result
sharp
loss
inhibitori
activ
cell
line
substitut
nitroquinolin
deriv
present
potent
inhibitori
effect
cell
line
chang
substitut
group
posit
result
clear
decreas
abil
inhibit
egfr
find
indic
anilin
moieti
substitut
play
import
role
inhibit
activ
thu
compound
chosen
benchmark
compound
subsequ
optim
studi
compound
retain
substitut
first
investig
among
compound
littl
activ
initi
molecular
model
experi
carri
investig
bind
interact
seri
compound
activ
site
egfr
conform
lowest
predict
bind
free
energi
occur
bind
mode
egfr
activ
pocket
select
final
model
compound
figur
atom
quinolin
form
hydrogen
bond
hydroxyl
group
thr
group
extend
deep
cleft
form
hydrogen
bond
interact
backbon
nh
moieti
group
point
entranc
activ
pocket
interestingli
oxygen
atom
group
form
hydrogen
bond
nh
orient
interact
protein
similar
observ
model
hydrogen
bond
atom
hydroxyl
group
thr
retain
model
group
displac
group
previous
hydrogen
bond
protein
instead
form
two
hydrogen
bond
backbon
nh
particularli
signific
interact
reenforc
perform
group
group
form
three
hydrogen
bond
respect
bind
mode
egfr
show
although
differ
conform
adopt
two
compound
egfr
activ
pocket
form
favor
hydrogen
bond
hydroxyl
group
thr
backbon
nh
report
previous
interact
backbon
nh
import
bind
atp
site
atp
inhibitor
explain
potent
respect
abil
inhibit
growth
egfroverexpress
cell
line
model
help
structur
elabor
novel
nitroquinolin
seri
improv
kinas
activ
ptk
catalyz
phosphoryl
transfer
group
atp
tyrosin
residu
protein
play
central
role
signal
transduct
cellular
mechan
src
nrtk
function
earli
upstream
signal
transduct
protein
activ
sever
human
cancer
includ
carcinoma
breast
lung
colon
esophagu
skin
parotid
cervix
well
gastric
tissu
therefor
attract
target
discoveri
antitumor
drug
quercetin
watersolubl
flavanoid
deriv
amelior
effect
host
disord
includ
cancer
renal
cardiovascular
diseas
inhibitori
activ
sarscov
pro
viral
replic
particularli
quercetin
wellknown
ptk
inhibitor
micromolar
level
instanc
ic
valu
egfr
src
tk
respect
indic
natur
product
activ
egfr
src
tk
last
decad
consider
interest
synthesi
function
elucid
biolog
evalu
quercetin
deriv
studi
focus
quercetin
oglycosid
major
sugar
linkag
acidest
neither
discov
natur
product
report
synthesi
bioactiv
studi
therefor
whether
type
compound
could
synthes
whether
still
activ
ptk
remain
unknown
seri
novel
acidest
synthes
huang
cowork
remark
compound
synthes
also
show
promis
high
select
inhibitori
activ
src
tk
prepar
varieti
quercetin
deriv
variou
substitu
effici
facil
synthesi
approach
develop
begin
commerci
avail
rutin
protect
hydroxyl
group
subsequ
deglycosyl
led
select
protect
quercetin
gave
entri
seri
substitut
posit
inde
still
exhibit
two
free
hydroxyl
group
howev
higher
reactiv
posit
allow
select
esterif
protect
amino
acid
thf
use
equiv
n
ndicyclohexylcarbodiimid
dcc
condens
agent
littl
dmap
catalyst
cleavag
benzyl
group
perform
hydrogenolysi
catalyz
pdc
desir
final
product
acidest
obtain
good
yield
purif
chromatographi
substitut
n
atom
amino
acid
moieti
import
first
attempt
get
compound
bear
deprotect
amino
group
amino
acid
moieti
trifluoroacet
acid
solut
dichloromethan
use
remov
tertbutyloxycarbonyl
group
howev
desir
product
detect
crude
product
target
compound
may
decompos
acid
medium
altern
approach
perform
mild
condit
investig
unfortun
attempt
debenzyl
compound
bear
benzyl
n
atom
amino
acid
moieti
h
atmospher
ambient
temperatur
success
base
studi
could
deduc
compound
without
protect
group
n
atom
unstabl
primari
assay
percent
inhibit
compound
measur
data
list
tabl
remark
newli
synthes
acidest
show
low
inhibit
egfr
kinas
wherea
exhibit
inhibitori
activ
high
src
kinas
tabl
result
suggest
novel
acidest
higher
inhibitori
select
src
kinas
egfr
kinas
thu
introduct
amino
acid
group
quercetin
lead
revers
high
inhibitori
select
egfr
src
confirm
bioactiv
ic
valu
determin
compound
inhibit
rate
higher
src
kinas
name
compound
tabl
data
show
eight
compound
promin
inhibitori
activ
ic
valu
rang
indic
acidest
moder
activ
inhibitor
src
kinas
bind
free
energi
quercetin
egfr
src
kinas
calcul
kcalmol
respect
good
agreement
experiment
result
quercetin
activ
egfr
src
kinas
therefor
dock
approach
paramet
reason
reliabl
predict
bind
free
energi
eight
new
compound
list
tabl
notic
predict
valu
new
compound
src
kinas
kcalmol
averag
stronger
kcalmol
egfr
kcalmol
averag
agreement
experiment
observ
eight
new
compound
stronger
inhibitor
src
kinas
egfr
kinas
therefor
select
newli
synthes
acidest
attribut
specif
properti
substitut
r
group
amino
acid
tabl
differ
conform
found
compound
activ
pocket
protein
comparison
differ
bind
mechan
pair
hydrophob
interact
hi
hereinaft
number
hydrogen
bond
hb
hereinaft
new
compound
two
target
analyz
program
ligplot
result
reveal
averag
hb
src
new
compound
averag
hb
egfr
compound
word
onethird
two
kind
interact
observ
compound
src
kinas
egfr
kinas
exampl
interact
detail
two
activ
compound
shown
figur
atom
form
hydrophob
interact
residu
src
atom
newli
substitut
group
figur
figur
interact
mechan
target
two
activ
ligand
b
compound
egfr
src
kinas
respect
c
compound
egfr
src
kinas
respect
atom
form
hydrophob
interact
two
residu
egfr
two
atom
substitut
group
figur
two
hydrogen
bond
form
src
four
hb
compound
egfr
regard
bind
hydrophob
interact
src
similar
egfr
four
hb
src
one
egfr
therefor
hydrophob
hydrogen
bond
interact
import
high
select
novel
acidest
src
kinas
studi
provid
new
promis
scaffold
moder
inhibitori
activ
ic
valu
rang
develop
new
anticanc
drug
target
src
tk
triazin
wide
studi
due
broad
rang
biolog
activ
antimicrobi
effect
erm
erythromycinresist
methylas
methyltransferas
inhibit
antitrypanosom
activ
integrin
late
antagon
estrogen
receptor
modul
cytotox
activ
base
find
avail
abund
trisubstitut
deriv
part
compound
screen
select
target
especi
tumor
cell
line
one
excit
screen
result
compound
nmorpholino
phenylamin
tabl
exhibit
moder
inhibit
activ
toward
one
cell
line
crc
inhibit
concentr
nowaday
crc
becom
one
major
cancer
threaten
peopl
live
american
cancer
societi
estim
new
case
colon
cancer
new
case
rectal
cancer
us
caus
death
though
death
rate
crc
go
past
year
continu
urgent
need
develop
new
potent
chemic
agent
find
compound
prompt
undertak
studi
vitro
inhibit
activ
triazin
deriv
substitut
subunit
morpholino
arylamino
toward
crc
cell
line
menicagli
et
al
report
nmorpholino
sever
nmorpholino
triazin
neglig
cytotox
activ
leukemia
cell
line
glioma
cell
line
nmorpholino
arylamin
n
diaryl
consid
consequ
seri
novel
nmorpholino
triaminotriazin
deriv
synthes
zheng
cowork
base
structur
featur
screen
hit
compound
design
synthes
first
round
keep
two
morpholino
group
compound
obtain
introduc
differ
electron
substitu
para
posit
phenyl
ring
substitut
phenyl
ring
benzyl
substitut
anilino
group
morpholino
gave
tri
nmorpholino
replac
one
morpholino
unit
compound
benzylamino
pmethylbenzylamino
anilino
unit
correspond
mononmorpholino
substitut
triazin
deriv
obtain
accord
bioassay
result
first
round
compound
design
synthes
tabl
use
n
diphenyl
benchmark
compound
compound
obtain
introduc
variou
steric
electron
hydrophob
group
one
phenyl
ring
compound
prepar
introduc
variou
substitu
phenyl
ring
displac
morpholino
unit
potent
compound
desir
amin
compound
prepar
tabl
compound
evalu
analyz
sulforhodamin
b
srb
sigma
assay
inhibitori
activ
toward
crc
cell
line
primari
assay
percent
inhibit
compound
concentr
measur
result
summar
tabl
shown
tabl
initi
compound
exhibit
potenti
inhibit
activ
toward
inhibit
concentr
respect
introduc
substitu
para
posit
phenyl
ring
compound
improv
inhibit
activ
substitut
anilino
unit
benzylamino
morpholino
result
complet
loss
inhibitori
activ
find
indic
anilino
group
compound
play
import
role
potent
inhibit
activ
crc
cell
line
mononmorpholino
substitut
triazin
deriv
present
potent
inhibitori
effect
correspond
nmorpholino
triazin
deriv
among
compound
littl
activ
initi
compound
inhibit
respect
dianilino
deriv
show
potent
activ
larg
improv
inhibitori
activ
comparison
inhibit
respect
thu
compound
chosen
benchmark
compound
subsequ
optim
studi
inhibitori
activ
second
round
compound
test
result
summar
tabl
compound
retain
morpholino
group
one
anilino
unit
first
investig
halogen
f
cl
br
substitut
deriv
demonstr
improv
activ
toward
howev
inhibit
activ
toward
decreas
electrondon
group
substitut
phenyl
ring
produc
excel
good
antiproliferatori
potenc
instanc
compound
ch
exhibit
high
inhibit
activ
toward
inhibit
respect
similar
potenc
compound
indic
methoxi
substitu
walk
phenyl
ring
littl
impact
inhibit
potenc
synergist
increas
activ
found
two
methoxysubstitut
deriv
toward
found
activ
inhibit
sulfanilamid
deriv
paminobenzamid
deriv
exhibit
high
inhibitori
activ
inhibit
respect
among
second
round
compound
four
compound
exhibit
signific
inhibitori
potenc
compound
substitu
two
phenyl
ring
show
similar
inhibit
potenc
benchmark
compound
howev
less
activ
pmethoxi
analog
decreas
potenc
toward
observ
throughout
subseri
compound
pfluoro
deriv
prove
virtual
inact
tabl
list
biolog
result
deriv
design
base
potent
inhibitor
compound
show
decreas
inhibitori
activ
toward
prove
complet
lost
inhibitori
activ
result
suggest
morpholino
subunit
directli
introduc
nuclear
import
determin
inhibitori
activ
toward
determin
exact
potenc
compound
exhibit
signific
inhibit
toward
compound
investig
concentrationrespons
studi
result
summar
tabl
compound
test
ic
compound
concentr
requir
growth
inhibit
tumor
cell
compound
show
moder
growth
inhibit
activ
ic
rang
compound
ic
promin
seri
compound
nearli
time
activ
benchmark
compound
ic
compound
test
ic
prove
potent
inhibitor
ic
valu
except
compound
among
compound
ic
ic
optim
one
time
activ
rel
benchmark
compound
ic
compound
potent
one
vitro
chosen
repres
one
class
triaminotriazin
undertak
studi
pharmacokinet
properti
vivo
antitumor
activ
pharmacokinet
pk
properti
assess
spraguedawley
rat
oral
administ
found
rapidli
absorb
gastrointestin
tract
mean
peak
concentr
c
max
achiev
min
oral
administr
compar
intraven
data
oral
bioavail
f
elimin
halfliv
oral
intraven
administr
h
respect
mean
resid
time
mrt
h
respect
distribut
volum
v
clearanc
cl
intraven
lhkg
respect
evalu
antitumor
efficaci
sarcoma
mice
model
compound
demonstr
modest
tumorinhibitori
activ
inhibit
dose
mgkgday
detail
experiment
data
shown
tabl
preliminari
vivo
antitumor
studi
pharmacokinet
studi
compound
show
might
promis
develop
new
antitumor
agent
past
year
cancer
chemotherapi
new
disciplin
develop
rapidli
discoveri
nitrogen
mustard
class
new
chemic
drug
discov
bring
great
benefit
cancer
patient
earli
stage
chemic
drug
employ
treat
tumor
expect
like
chemic
knife
replac
surgic
knife
use
quit
limit
afterward
varieti
chemic
agent
cure
kind
malign
tumor
also
use
combin
modal
treat
differ
cancer
remark
efficaci
recent
year
moleculartarget
drug
discov
help
cancer
chemotherapi
enter
new
era
select
action
less
toxic
base
molecular
oncolog
molecular
pharmacolog
modern
genet
engin
well
comput
simul
technolog
mean
dock
simul
crystal
structur
virtual
screen
method
new
chemic
agent
recent
design
synthes
act
specif
gene
regul
cancer
cell
prolifer
divis
differenti
apoptosi
metastat
process
known
imantinib
gefitinib
erlotinib
smallmolecul
egfrtyrosinekinas
inhibitor
treat
chronic
myelocyt
leukemia
gastrointestin
stromal
tumor
gist
nonsmal
cell
lung
cancer
tumor
effect
action
mechan
kill
cancer
cell
former
cytotox
agent
definit
influenc
signal
transduct
gene
express
cancer
cell
chemic
substanc
select
activ
regul
normal
process
tumor
growth
progress
progress
newli
develop
molecular
target
therapi
combin
effect
method
greatli
inspir
research
control
cancer
diseas
hope
futur
chemic
anticanc
agent
use
purpos
cure
cancer
also
prevent
repair
recov
malign
process
go
chemic
knife
chemic
regul
modul
import
difficult
task
investig
confid
success
futur
abovement
data
seen
progress
cancer
chemotherapeut
drug
research
china
advanc
quickli
mani
anticanc
drug
includ
compound
natur
origin
contain
tcm
product
synthet
agent
inhibitor
topoisomeras
tumor
angiogenes
well
effect
prepar
success
investig
develop
clinic
use
product
within
rel
short
period
time
lot
lead
compound
new
drug
candid
discov
chines
scientist
help
futur
investig
undoubtedli
valuabl
work
play
favor
role
caus
cancer
prevent
therapi
chapter
aim
help
peopl
find
origin
work
area
achiev
contribut
mani
organ
pharmaceut
factori
china
may
found
public
hope
greater
success
creativ
work
field
discov
new
effect
drug
appear
next
decad
control
neoplast
diseas
